EyePoint (EYPT) Depreciation & Amortization (CF) (2024 - 2026)
EyePoint (EYPT) posted Depreciation & Amortization (CF) of $636000.0 for Q1 2026, up 30.06% sequentially from $489000.0 in Q4 2025, and up 27.97% YoY from $497000.0 in Q1 2025.
Analysis
EyePoint (EYPT) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
EyePoint has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $636000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 27.97% year-over-year to $636000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 29.12% YoY) and the FY2025 annual result came in at $2.3 million, up 49.94% from the prior year.
- Depreciation & Amortization (CF) grew to $636000.0 in Q1 2026 per EYPT's latest filing, from $489000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $636000.0 in Q1 2026 and troughed at $81000.0 in Q1 2022.
- A 5-year average of $302117.6 and a median of $303000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) dropped 13.85% in 2023, then jumped 316.96% in 2024.
- Over 5 years, Depreciation & Amortization (CF) stood at $130000.0 in 2022, then slipped by 13.85% to $112000.0 in 2023, then soared by 316.96% to $467000.0 in 2024, then gained by 4.71% to $489000.0 in 2025, then surged by 30.06% to $636000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $636000.0, $489000.0, and $576000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 690,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 690,000.00 |
| Mar 31, 2026 | 636,000.00 |
| Jun 30, 2025 | 538,000.00 |
| Mar 31, 2025 | 497,000.00 |
| Dec 31, 2024 | 467,000.00 |